Macquarie Group picks the 3 best healthcare stocks for 2019

Healthcare stocks have been among the stars of the latest reporting season as the sector outperformed the S&P/ASX 200 (Index:^AXJO) (ASX:XJO). But which stocks should you be buying?

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Healthcare stocks have been among the stars of the latest reporting season as a number have beaten market expectations as their defensive earnings profile appeal to those seeking shelter from the macroeconomic volatility.

Their outperformance is evidenced by the close to 5% gain in the S&P/ASX 200 Health Care (Index:^AXHJ) (ASX:XHJ) index since mid-February (as the reporting season got into full swing), compared to the 2.4% increase in the broader S&P/ASX 200 (Index:^AXJO) (ASX:XJO).

The key contributors to the ASX 200 Heath Care index gains include the Ramsay Health Care Limited Fully Paid Ord. Shrs (ASX: RHC) share price, Sonic Healthcare Limited (ASX: SHL) and Ansell Limited (ASX: ANN).

Mind you, not all healthcare stocks are well placed to deliver healthy returns in 2019 (mind the pun). If you are wondering where the best opportunities are in the sector, Macquarie Group Ltd (ASX: MQG) have a few tips for you as the broker reviews the latest set of profit results.

Three healthcare stocks for 2019

"There were a number of surprises recorded across our sector coverage over the 1H19 reporting season," said Macquarie.

"In our view, the most significant upside surprises related to RHC (a better than expected operational result in France, favourable UK tariff outcomes) and ANN (a better than expected 1H19 result, upgraded FY19 guidance)."

The strong results from the hospital operator Ramsay and glove maker Ansell gave the broker another reason to add them to its most preferred list of healthcare stocks, which also includes blood products maker CSL Limited (ASX: CSL).

No surprises that Macquarie rates all three as "outperform". It likes CSL for its market leadership in the plasma collection market, growth of higher margin products and the upside from the Seqirus acquisition into FY20.

The broker also has a bullish view on Ramsay due to improving French and UK market dynamics (it has hospitals in those countries), contributions from recently completed Australian brownfield developments and further scope for cost savings.

Meanwhile, Ansell's upside comes from its transformation program, price increases for its products and the strength of its balance sheet, which can support earnings-accretive acquisitions and/or capital management initiatives.

From darlings to dustpans

But it's not all good news. There are some healthcare icons that didn't make the cut. These are our largest medical device makers, Cochlear Limited (ASX: COH) and RESMED/IDR UNRESTR (ASX: RMD).

"Conversely, we see COH (flat unit sales growth in developed markets) and RMD (weaker than expected RoW [rest of the world] devices sales growth) as recording the most substantial negative surprises relative to our expectations," said Macquarie.

The broker has slapped an "underperform" recommendation on both stocks.

Motley Fool contributor Brendon Lau owns shares of CSL Ltd., Macquarie Group Limited, and ResMed Inc. The Motley Fool Australia has recommended Ansell Ltd., Cochlear Ltd., Ramsay Health Care Limited, and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »